🇺🇸 FDA
Pipeline program

Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of neuroinflammation (SMART in MS)

APHP200056

Phase 3 other active

Quick answer

Remyelination in Multiple Sclerosis: a PET-MR longitudinal study investigating individual profiles of myelin repair and the contribution of neuroinflammation (SMART in MS) for Remyelination in Multiple Sclerosis is a Phase 3 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Remyelination in Multiple Sclerosis
Phase
Phase 3
Modality
other
Status
active

Clinical trials